Fresenius Kabi Launches Tyenne, the First Tocilizumab Biosimilar Approved in Spain

Another step forward for medicine. German global health company Fresenius Kabi launches Tyenne, the first tocilizumab biosimilar approved in Spain. The company specializes in biopharmaceuticals, clinical nutrition, medical technologies, and generic intravenous medications for critical and chronic conditions, according to the pharmaceutical company’s statement.

Tyenne is the first tocilizumab biosimilar available in the European Union (EU) for the treatment of several inflammatory and immune system diseases, including rheumatoid arthritis, giant cell arteritis, polyarticular juvenile idiopathic arthritis, systemic juvenile idiopathic arthritis, cytokines (SLC), as well as for the treatment of Covid-19.

Montse Planas, general director of Fresenius Kabi Spain, explains that “the launch of Tyenne is a very important step in our effort to improve the quality of life of the patient and the professional; Our status as pioneers, by offering a biosimilar of tocilizumab in the EU, shows that we are determined to be leaders in the field of biopharmaceuticals,” according to the directive.

Dr. Michael Schönhofen, President of Fresenius Kabi Biopharmaceuticals, adds: “We are very proud to be the first company to introduce an alternative, affordable, high-quality, and safe treatment option of tocilizumab for healthcare providers and patients living with chronic diseases. inflammatory and immune system.

If you want to find out more about the German company Fresenius and the launch of Tyenne, download for free our companion app. The Born2Invets mobile app keeps its readers up to date with the most important business news of the day so they can stay on top of the market.

Tyenne becomes the second biosimilar of Fresenius Kabi available in the Spanish market

The manager adds that “by offering both subcutaneous and intravenous administrations, we believe Tyenne will transform the treatment landscape, improve outcomes for patients, and reduce the financial burden on both those affected and health systems.”

Tyenne thus becomes the second biosimilar of Fresenius Kabi available in the Spanish market, which already had Idacio 3 (adalimumab). Fresenius Kabi is working on expanding its portfolio of biosimilars for autoimmune diseases and oncology, with several molecules in advanced stages of development.

Fresenius Kabi is a global healthcare company specializing in medicines and technologies for infusion, transfusion, and clinical nutrition. Its products and services are used to care for critical and chronic patients.  

​​​​​Its product portfolio comprises a range of generic intravenous medications, infusion therapies, and clinical nutrition products, as well as the devices to deliver these products. In 2019, the first Fresenius Kabi biosimilar product was launched.

__

(Featured image by Ajale via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.